High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma.
An HPLC assay was developed to determine the paclitaxel analogue 13-(N-tert.-butoxycarbonyl-beta-isobutylisoserinyl)-14-hydroxyb accatin-1,14-carbonate (IDN5109) and its epimer in mouse plasma. The method involves solid-phase extraction on cyano cartridges (recovery >75%), HPLC separation on symmetry shield column, a mobile phase of NaH2PO4 (10 mM) pH 5.2, acetonitrile (47:53) and detection at 227 nm. Retention times of IDN5109, its epiform and internal standard were 15, 24 and 25.5 min, respectively. The assay was linear from 0.10 to 10 microg/ml (r2 = 0.999), with a C.V. <5% and accuracy in the range of 95-107%. LOQ was 50 ng/ml for both compounds. Using this method IDN5109 pharmacokinetic was determined in mice.
Colombo
T
T
Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Frapolli
R
R
Bombardelli
E
E
Morazzoni
P
P
Riva
A
A
D'Incalci
M
M
Zucchetti
M
M
D000818:Animals; D001952:Bridged-Ring Compounds / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D005260:Female; D005615:Freezing; D007700:Kinetics; D051379:Mice; D017239:Paclitaxel / Q000031:analogs & derivatives*; D011786:Quality Control; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D043823:Taxoids
D001952:Bridged-Ring Compounds; D043823:Taxoids; C404743:IDN 5109; D017239:Paclitaxel